A Single Ascending Dose and Relative Bioavailability Study of LY2940680 in Healthy Subjects

Trial Profile

A Single Ascending Dose and Relative Bioavailability Study of LY2940680 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2013

At a glance

  • Drugs Taladegib (Primary) ; Lansoprazole
  • Indications Cancer; Dyspepsia; Gastro-oesophageal reflux; Heartburn; Helicobacter infections; NSAID-induced ulcer; Peptic ulcer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 11 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top